BioAdaptives, Inc. Files 8-K
Ticker: BDPT · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1575142
| Field | Detail |
|---|---|
| Company | Bioadaptives, INC. (BDPT) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, financials, regulation-fd
TL;DR
BioAdaptives filed an 8-K on May 20, 2024, covering Reg FD, other events, and financials.
AI Summary
BioAdaptives, Inc. filed an 8-K on November 20, 2024, reporting events as of May 20, 2024. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. The company, formerly known as APEX 8 Inc., is incorporated in Delaware and based in Las Vegas, Nevada.
Why It Matters
This 8-K filing provides updates on BioAdaptives, Inc.'s corporate activities and financial reporting, which are crucial for investors to understand the company's current status and regulatory compliance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks or material adverse information.
Key Players & Entities
- BIOADAPTIVES, INC. (company) — Registrant
- APEX 8 Inc. (company) — Former company name
- 20241120 (date) — Filing date
- 20240520 (date) — Earliest event reported date
- 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128 (location) — Principal Executive Office Address
FAQ
What is the primary purpose of this 8-K filing for BioAdaptives, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures, other events, and financial statements and exhibits as of May 20, 2024.
When was BioAdaptives, Inc. formerly known as?
BioAdaptives, Inc. was formerly known as APEX 8 Inc., with a date of name change on April 24, 2013.
What is the principal executive office address for BioAdaptives, Inc.?
The principal executive office address for BioAdaptives, Inc. is 2620 Regatta Drive, Suite 102, Las Vegas, Nevada 89128.
What is the Standard Industrial Classification (SIC) code for BioAdaptives, Inc.?
The Standard Industrial Classification (SIC) code for BioAdaptives, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 8-K report?
This 8-K report was filed as of date November 20, 2024.
Filing Stats: 406 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-11-20 17:05:58
Filing Documents
- bdpt_8k.htm (8-K) — 22KB
- bdpt_ex991.htm (EX-99.1) — 27KB
- bdpt_8kimg2.jpg (GRAPHIC) — 5KB
- 0001640334-24-001769.txt ( ) — 180KB
- bdpt-20240520.xsd (EX-101.SCH) — 6KB
- bdpt-20240520_lab.xml (EX-101.LAB) — 13KB
- bdpt-20240520_cal.xml (EX-101.CAL) — 1KB
- bdpt-20240520_pre.xml (EX-101.PRE) — 8KB
- bdpt-20240520_def.xml (EX-101.DEF) — 2KB
- bdpt_8k_htm.xml (XML) — 3KB
01: Other Events
Item 8.01: Other Events. On November 20, 2024, FINRA approved BioAdaptives Inc.'s Reverse split. The reverse split becomes effective on November 21, 2024.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure FINRA requires a letter to the shareholders regarding the Company issued a press release on October 29, 2024, reporting the impending reverse split. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is being furnished and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise be subject to the liabilities of that section, nor is it incorporated by reference into any filing of the Company, under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release 2 SIGNATURE Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. November 20, 2024 BioAdaptives, Inc. /s/ James Keener James Keener Director and CEO 3